Search results
Argatroban (Argatra®) Control Plasma
Quality control of clotting assays proposed for measuring argatroban concentrations in plasma (especially ref. CK002K, CK002L).
Bivalirudin (Angiox®) Plasma Control
Quality control of clotting assays proposed for measuring bivalirudin concentrations in plasma (especially ref. CK002K, CK002L and 220202).
Dabigatran (Pradaxa®) Control Plasma
Quality control titrated and optimized for anti-IIa colorimetric assays (HEMOCLOT Thrombin Inhibitors: ref. CK002K/CK002L).
Dabigatran (Pradaxa®) Control Plasma (low range)
Quality control titrated and optimized for anti-IIa colorimetric assays (HEMOCLOT Thrombin Inhibitors: ref. CK002K/CK002L).
BIOPHEN FVIIa Control Set
BIOPHEN FVIIa Control Set is a set of controls intended for the quality control of activated factor VII (FVIIa) activity measurements, the BIOPHEN FVIIs colorimetric assay with the kit BIOPHEN Factor VIIa (ref. 221312) and the clotting assay with the kit HEMOCLOT Factor VIIa assay (ref. CK092K).
Emicizumab Controls
Quality control of a modified one-stage FVIII activity assay for determination of active emicizumab concentration from a clot time measurement performed on an automated coagulation analyzer.
BIOPHEN FIXa Control Set
Factor IXa controls are intended for the quality control of activated factor IX (FIXa) chromogenic measurements, using BIOPHEN Factor IXa assay (ref. 221812). For research use only.
FIXa Controls (ultra low)
Factor IXa controls are intended for the quality control of activated factor IX (FIXa) chromogenic measurements (approx. 0.2 mIU/mL), using BIOPHEN Factor IXa assay (ref. 221812).
FIXa Controls (ultra low)
Factor IXa controls are intended for the quality control of activated factor IX (FIXa) chromogenic measurements (approx. 1.3 mlU/mL), using BIOPHEN® Factor IXa assay (ref. 221812).
BIOPHEN FXIa Controls
FXIa Controls are proposed for the quality control of FXIa measurements, in therapeutic concentrates or in purified milieus, using Biophen FXIa kit (ref. 220412) For research use only.